Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.

@article{Vaccaro2012AdditionOE,
  title={Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.},
  author={Olga Vaccaro and Maria Masulli and Enzo Bonora and Stefano Del Prato and Carlo Bruno Giorda and Aldo Pietro Maggioni and Paolo Mocarelli and Antonio Nicolucci and Angela Albarosa Rivellese and Sebastiano Squatrito and Gabriele Riccardi},
  journal={Nutrition, metabolism, and cardiovascular diseases : NMCD},
  year={2012},
  volume={22 11},
  pages={997-1006}
}
BACKGROUND AND AIMS Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Società Italiana di Diabetologia e Associazione Medici Diabetologi ( SID e AMD ) working group on the standards of care for diabetes . Highlights from Italian standards of care for diabetes mellitus

  • G Bruno, A DeMicheli, S Frontoni, L Monge
  • Diabetologia
  • 2012

Similar Papers

Loading similar papers…